MAP2K7 and melanoma: A major part of the current standard therapeutic strategy for melanoma includes a range of targeted treatment entities based on specific gene mutations (BRAF inhibitors), pathways or enzymes (MEK inhibitors, tyrosine kinase inhibitors) and growth factors (VEGF inhibitors) [6, 19, 53-60].